| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
STING[1]
IACS-8803 targets STING (TMEM173), an innate immune sensor. It binds STING and activates the STING-TBK1-IRF3 signaling axis, inducing interferon gene expression and type I interferon production. This promotes dendritic cell maturation, antigen presentation, and T-cell priming, resulting in systemic antitumor immunity. It also induces programmed necrotic cell death in some tumor types. |
|---|---|
| ln Vitro |
In vitro, IACS-8803 activates the STING pathway in reporter cell lines expressing human and mouse STING. Potency is assessed using THP1-Dual and 293-Dual reporter cells. It induces strong activation of the STING pathway and shows superior activity to benchmark STING agonists. In ex vivo meningioma models, IACS-8803 at 10 µM induces programmed necrotic cell death.
|
| ln Vivo |
The B16 murine model of melanoma demonstrates a better systemic anti-tumor response when treated with IACS-8803[1].
In vivo, IACS-8803 shows a superior systemic antitumor response in the B16 murine melanoma model compared to clinical benchmark compounds. Intratumoral administration induces regression of both injected and untreated contralateral tumors. It also shows efficacy in pancreatic cancer models and in canine companion animals with glioblastoma. |
| Enzyme Assay |
For non-cell assays, recombinant STING protein is incubated with IACS-8803 and a fluorescent STING ligand. Binding affinity is measured by fluorescence polarization or surface plasmon resonance. STING activation is assessed by measuring TBK1 phosphorylation in cell-free systems using purified STING, TBK1, and ATP.
|
| Cell Assay |
In cell assays, THP1-Dual or 293-Dual reporter cells expressing human or mouse STING are treated with serial dilutions of IACS-8803. STING pathway activation is measured by luciferase reporter activity driven by IRF3 or NF-κB. Western blot is used to evaluate STING pathway activation. MTT assays determine direct effects on cell viability.
|
| Animal Protocol |
In vivo animal protocols use mice implanted with B16 melanoma or other syngeneic tumor models. IACS-8803 is administered intratumorally at doses of 5-10 µg per injection, typically three injections. Tumor growth on both injected and untreated contralateral flanks is measured. Systemic immune responses, survival, and cure rates are assessed. Canine studies use companion animals with spontaneous glioblastoma.
|
| References |
| Molecular Formula |
C20H23FN10O9P2S2
|
|---|---|
| Molecular Weight |
692.53
|
| Exact Mass |
692.055
|
| CAS # |
2095690-70-1
|
| Related CAS # |
IACS-8803 disodium;2243079-36-7;IACS-8803 diammonium
|
| PubChem CID |
163491249
|
| Appearance |
White to yellow solid powder
|
| LogP |
-1.4
|
| tPSA |
285
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
44
|
| Complexity |
1180
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
OC1([H])[C@@]2([H])COP(S)(=O)O[C@@]3([H])[C@@H](F)[C@H](N4C=NC5=C(N=CN=C45)N)O[C@]3([H])CO[P@](S)(=O)O[C@]1([C@H](N1C=NC3=C(N=CN=C13)N)O2)[H]
|
| InChi Key |
CMVAAKLGZJHFOY-ILOIOECTSA-N
|
| InChi Code |
InChI=1S/C20H23FN10O9P2S2/c21-9-13-8(38-19(9)30-5-28-10-15(22)24-3-26-17(10)30)2-36-42(34,44)40-14-12(32)7(1-35-41(33,43)39-13)37-20(14)31-6-29-11-16(23)25-4-27-18(11)31/h3-9,12-14,19-20,32H,1-2H2,(H,33,43)(H,34,44)(H2,22,24,26)(H2,23,25,27)/t7-,8-,9-,12?,13-,14-,19-,20-,41?,42?/m1/s1
|
| Chemical Name |
(1R,6R,8R,9R,10R,15R,17R)-8,17-bis(6-aminopurin-9-yl)-9-fluoro-12-hydroxy-3-oxo-3-sulfanyl-12-sulfanylidene-2,4,7,11,13,16-hexaoxa-3λ5,12λ5-diphosphatricyclo[13.2.1.06,10]octadecan-18-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~15 mg/mL (~21.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4440 mL | 7.2199 mL | 14.4398 mL | |
| 5 mM | 0.2888 mL | 1.4440 mL | 2.8880 mL | |
| 10 mM | 0.1444 mL | 0.7220 mL | 1.4440 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.